as an AI-designed drug for OCD treatment is to enter human clinical trials for the first time. The drug developed by Oxford-based AI start-up Exscientia (in collaboration with Sumitomo Dainippon Pharma, a Japanese firm) is nothing short of a breakthrough having reached clinical trials in just 12 months. A stark contrast to the typical development time of four and a half years, the development shows the exciting potential of the application of AI in the health sector.
Sir John Bell, the Regius professor of medicine at Oxford university comments as follows:
“The design and development of molecules through medicinal chemistry has always been a slow and laborious process... Exscientia can do this in many fewer steps, which is really impressive, and it comes from very sound scientific principles. I think they are a real asset to have in the UK.”